Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 58,600 shares, a decrease of 52.9% from the January 31st total of 124,500 shares. Currently, 5.5% of the company’s stock are sold short. Based on an average daily volume of 2,240,000 shares, the short-interest ratio is presently 0.0 days.

Evaxion Biotech A/S Stock Performance

Evaxion Biotech A/S stock traded down $0.05 during mid-day trading on Monday, reaching $1.89. 125,281 shares of the company traded hands, compared to its average volume of 3,551,884. Evaxion Biotech A/S has a fifty-two week low of $1.78 and a fifty-two week high of $22.05. The firm’s fifty day moving average is $3.35 and its two-hundred day moving average is $9.08. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. The company has a market capitalization of $2.22 million, a price-to-earnings ratio of -1.30 and a beta of -0.28.

Hedge Funds Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC acquired a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S as of its most recent filing with the Securities and Exchange Commission (SEC). 11.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EVAX. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Thursday, February 20th. Lake Street Capital lowered their price target on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 4th.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.